Thursday, January 23, 2025

Next China: A good start

Will the China-Trump good vibes last?
View in browser
Bloomberg

Next China is now exclusively for Bloomberg.com subscribers. As a loyal reader, we'll keep sending it to you for a limited time. If you'd like to continue receiving Next China, and gain unlimited digital access to all of Bloomberg.com, we invite you to subscribe now at a special rate.

Hi, this is Philip Glamann in Beijing, where everyone is looking forward to the long Lunar New Year holiday.

Well, that and what happens between China and the US during the second go-round of President Donald Trump.

An optimist (there must be some out there) might be cautiously hopeful that the relative peace this week augurs well for the next four years. Trump held off on blasting China with tariffs right away. Read our story about Beijing avoiding early levies here.

Instead, he ordered a broad probe into the trade practices of nations including China that is due April 1. This move could signal a desire to head to the negotiating table and cut a deal like the one reached with Beijing in his first term.

Trump did say he was still open to tariffs of 10% on Chinese products to punish Beijing for, in his view, failing to stop the flow of fentanyl into the US. Yet that's a far cry from the broad 60% level he pledged to slap on shipments from the country on the campaign trail.

On top of that, fentanyl was one area where the Biden administration had some success talking to Beijing, so maybe China and Trump could come to terms on the issue.

Trump also held off on the TikTok ban, giving the video-sharing platform 75 days to find a buyer or go dark for good. He later suggested billionaire backer Elon Musk or Oracle Chairman Larry Ellison buy the app in a JV with Uncle Sam.

And one last positive: The new US leader has apparently also hinted he's interested in visiting China early in his second term, which if true would suggest he's going to avoid openly antagonizing Beijing before making a journey.

That's all well and good but on the flip side …

A more skeptical person (*coughs*) can be forgiven for seeing some fundamental reasons things will go haywire eventually.

Top of the list? China's trade surplus soared to record of nearly $1 trillion just before Trump took office. Given the priority he places on evening out commerce, that may be all the reason anyone needs to think that eventually push will come to shove.

Chinese Vice Premier Ding Xuexiang said in Davos, Switzerland, that his nation doesn't want a surplus but rather "to import more competitive, quality products and services to promote balanced trade." Read our story about Ding's Davos trip here.

The vice premier thought to be close to President Xi Jinping didn't go into details. But if he means things like semiconductors and other high-tech goods, it's pretty unlikely the US will play ball considering it sees keeping an edge there as a national security necessity.

Additionally, China's skittish consumers are holding back any economic recovery because wage gains are sluggish and the job market gloomy. It's fair to say they're not exactly itching to snap up some of those imports Ding welcomes.

Then there's the fact that the Trump Cabinet is replete with China hawks. Take Marco Rubio, the new secretary of state, who's made clear over his career he's no fan of Beijing's policies.

The feeling is mutual in China, which back in 2020 hit him with sanctions. Chinese state media once even called him a "political weirdo."

China has indicated it's open to dealing with Rubio but the idea of him visiting Beijing and warmly shaking hands with officials like his predecessor, Antony Blinken, does seem, well, fairly far-fetched right now.

Marco Rubio, the US new secretary of state. Photographer: Oliver Contreras/Sipa

Rubio likely gave a preview of new US foreign policy toward China on his first day on the job, when he met counterparts in the Quad. Beijing strongly dislikes the idea of the diplomatic grouping that includes India, Japan and Australia, seeing it as a tool to limit its rise.

Rubio later described US defense commitments to the Philippines as "ironclad," and criticized Beijing's "dangerous and destabilizing actions in the South China Sea." Neither comment does much to endear the former senator to Beijing.

Most people in China will be kicking off the holiday soon, hoping for a bit of relaxation as they reunite with family. We'll see just how the peace lasts.

Editor's note: The Next China newsletter won't publish next week because of the holiday. It returns on Feb. 7.

What We're Reading, Listening to and Watching:

Two Thumbs Up

China's cinephiles had a good 2024 because they got to see more movies from the rest of world.

The flow of Hollywood flicks into the country had slowed to a trickle in recent years, a casualty of the trade war but also because people were content watching domestically made movies telling relatable stories.

Yet last year more US films and hits from India (Maharaja) and Japan (The Boy and the Heron) returned to the world's No. 2 market.

In a rarity, censors even let the R-rated Joker: Folie à Deux screen. (Like film fans elsewhere, people in China were a bit thrown by the dark musical/thriller.)

A Xenomorph runs amok at a Shanghai screening of Alien: Romulus. Photographer: CFOTO/CFOTO

The blockbuster spree stood out in a market that saw overall box office receipts slump to a decade low, excluding the pandemic. Read our story about that here.

The Chinese government is deeply conflicted about allowing in foreign cultural influences but it gave the nod to 93 new imports last year, the most since 2019.

Why the plot twist? To try to spur anemic consumer spending. Getting people into theaters is a decent idea given most Chinese cinemas are in shopping malls, home to all those luxury brand stores, phone and EV outlets, and restaurants.

Officials also seem keen for people to watch movies over the holidays. They rolled out subsidies worth the equivalent of some $82 million for ticket purchases from December to February. Some local governments are handing out similar vouchers.

One of China's biggest holidays, Lunar New Year, is just days away. Afterward, data on movie tickets sold, trips made and tourism spending will be studied to try to get a sense of how the consumer is feeling.

That's important because while exports have soared, the consumer sector has yet to pitch in enough to help the economic recovery.

Whether China's film fans will continue to enjoy the variety of offerings is an open question. If things go south between Trump and Xi, it's easy to see China cutting off the flow of US films again. A spat with Japan or India could do the same.

Still, a top ticketing website shows that Chinese moviegoers are looking forward to several film imports this 2025. Those include – get this – Captain America: Brave New World.

Hint, hint

$925
That's the cost of a bottle of shiraz varietal — notes of ripe berries, black cherries and chocolate, with a tannic undercurrent — that Australian winemaker Penfolds is selling especially for the upcoming Year of the Snake. Straight cash in a red envelope is preferred by many people in China, but for snazzier Lunar New Year present ideas, including a Parmigiani Fleurier wristwatch, check out our Pursuits gift guide.

Behind the Great Firewall

A weekly look at the big water cooler news in China.

Worries about the safety of China's food and medicines resurfaced this week, much to the frustration of the public.

At issue were the cheap generics that have replaced big-name Western drugs in China's hospitals as part of the government's push to cut health costs. The public alarm kicked off because doctors told the media that some generic drugs seemed to have quality issues.

China has been shifting toward wider use of generic medicines in recent years. Photographer: Chris Ratcliffe/Bloomberg

Zheng Minhua, a senior surgeon at the prestigious Ruijin Hospital in Shanghai, told Caixin that some hypertension meds didn't work effectively and that anesthetics failed to knock patients out.

Over the past six years, the government's system for procuring medicines has seen off-patent versions from global pharmaceutical giants such as AstraZeneca and Pfizer replaced by similar drugs made by domestic firms, often at a fraction of the price.

The program has saved Beijing billions of dollars, money it has used to reimburse patients for expensive innovative therapies, including many developed by Western drugmakers.

While the domestic generics have passed tests showing they work as well as the brand-name medicines, since last year there has been growing chatter among patients and doctors that the quality is off.

"What's the point of paying for the state medical insurance scheme when the medicines no longer work?" one person asked on Weibo, which is similar to X.

"Well, how do the senior cadres get their medicine then?" wrote another, hinting at widespread public suspicion that top members of the ruling Communist Party enjoy privileges unavailable to the average person.

Given China's history of problems with food and drug safety, the latest bout of public discontent is understandable. People remember how tainted milk in 2008 killed six babies and made some 300,000 ill. There was also a scandal last year over tanker trucks filling up with cooking oil right after carrying an inedible oil.

The Chinese government is very much aware that the public is worried about the quality of the things they put in their bodies. That explains why the National Healthcare Security Administration, overseer of the country's health insurance plan, quickly said it would look into the generic drug issue.

We'll see if the latest scandal impacts how officials handle a possible new round of procurement later this year.

Follow Us

Like getting this newsletter? There's more where that came from. Browse all our weekly and daily emails to get even more insights from your Bloomberg.com subscription.

Before it's here, it's on the Bloomberg Terminal. Find out more about how the Terminal delivers information and analysis that financial professionals can't find anywhere else. Learn more.

Want to sponsor this newsletter? Get in touch here.

You received this message because you are subscribed to Bloomberg's Next China newsletter. If a friend forwarded you this message, sign up here to get it in your inbox.
Unsubscribe
Bloomberg.com
Contact Us
Bloomberg L.P.
731 Lexington Avenue,
New York, NY 10022
Ads Powered By Liveintent Ad Choices

No comments:

Post a Comment

Brussels Edition: Courting Trump

Welcome to the Brussels Edition, Bloomberg's daily briefing on what matters most in the heart of the European Union.Europe is qu...